The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC).
Andreas Schneeweiss
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Julia Aigner
No relevant relationships to disclose
Katherina Smetanay
No relevant relationships to disclose
Florian Schuetz
No relevant relationships to disclose
Christof Sohn
No relevant relationships to disclose
Mark Kriegsmann
No relevant relationships to disclose
Dirk Jaeger
No relevant relationships to disclose
Markus Zorn
No relevant relationships to disclose
Andreas Bachinger
No relevant relationships to disclose
Hans-Peter Sinn
Research Funding - Celgene
Frederik Marme
Honoraria - Celgene